SG10201601153RA - Method for detecting nucleosomes containing nucleotides - Google Patents

Method for detecting nucleosomes containing nucleotides

Info

Publication number
SG10201601153RA
SG10201601153RA SG10201601153RA SG10201601153RA SG10201601153RA SG 10201601153R A SG10201601153R A SG 10201601153RA SG 10201601153R A SG10201601153R A SG 10201601153RA SG 10201601153R A SG10201601153R A SG 10201601153RA SG 10201601153R A SG10201601153R A SG 10201601153RA
Authority
SG
Singapore
Prior art keywords
containing nucleotides
nucleosomes containing
detecting nucleosomes
detecting
nucleotides
Prior art date
Application number
SG10201601153RA
Inventor
Jacob Vincent Micallef
Original Assignee
Singapore Volition Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Volition Pte Ltd filed Critical Singapore Volition Pte Ltd
Publication of SG10201601153RA publication Critical patent/SG10201601153RA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
SG10201601153RA 2011-09-01 2012-08-31 Method for detecting nucleosomes containing nucleotides SG10201601153RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530295P 2011-09-01 2011-09-01
GBGB1115095.0A GB201115095D0 (en) 2011-09-01 2011-09-01 Method for detecting nucleosomes containing nucleotides

Publications (1)

Publication Number Publication Date
SG10201601153RA true SG10201601153RA (en) 2016-03-30

Family

ID=44882046

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201601153RA SG10201601153RA (en) 2011-09-01 2012-08-31 Method for detecting nucleosomes containing nucleotides
SG11201400270PA SG11201400270PA (en) 2011-09-01 2012-08-31 Method for detecting nucleosomes containing nucleotides

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201400270PA SG11201400270PA (en) 2011-09-01 2012-08-31 Method for detecting nucleosomes containing nucleotides

Country Status (22)

Country Link
US (2) US10900064B2 (en)
EP (2) EP3483608B1 (en)
JP (1) JP6322845B2 (en)
KR (1) KR102074528B1 (en)
CN (1) CN104067124B (en)
AU (1) AU2012300641B2 (en)
BR (1) BR112014005087B1 (en)
CA (1) CA2845993C (en)
DK (1) DK2751568T3 (en)
ES (1) ES2717659T3 (en)
GB (1) GB201115095D0 (en)
HK (1) HK1199760A1 (en)
HR (1) HRP20190533T1 (en)
HU (1) HUE043386T2 (en)
MX (1) MX364410B (en)
PL (1) PL2751568T3 (en)
PT (1) PT2751568T (en)
RU (2) RU2687483C2 (en)
SG (2) SG10201601153RA (en)
TR (1) TR201904386T4 (en)
WO (1) WO2013030577A1 (en)
ZA (1) ZA201401295B (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10083273B2 (en) 2005-07-29 2018-09-25 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US10081839B2 (en) 2005-07-29 2018-09-25 Natera, Inc System and method for cleaning noisy genetic data and determining chromosome copy number
CN102171565B (en) 2008-08-04 2015-04-29 纳特拉公司 Methods for allele calling and ploidy calling
ES2640776T3 (en) 2009-09-30 2017-11-06 Natera, Inc. Methods for non-invasively calling prenatal ploidy
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
EP2572003A4 (en) 2010-05-18 2016-01-13 Natera Inc Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
ES2770342T3 (en) 2010-12-22 2020-07-01 Natera Inc Noninvasive Prenatal Paternity Testing Procedures
JP6153874B2 (en) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド Method for non-invasive prenatal ploidy calls
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
EP2775304A1 (en) * 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
US9499870B2 (en) * 2013-09-27 2016-11-22 Natera, Inc. Cell free DNA diagnostic testing standards
US10577655B2 (en) 2013-09-27 2020-03-03 Natera, Inc. Cell free DNA diagnostic testing standards
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
RU2717641C2 (en) 2014-04-21 2020-03-24 Натера, Инк. Detection of mutations and ploidy in chromosomal segments
WO2016049936A1 (en) * 2014-09-30 2016-04-07 Bgi Shenzhen Co., Limited Biomarkers for rheumatoid arthritis and usage therof
DK3213084T4 (en) 2014-10-29 2024-03-18 Belgian Volition Sprl PROCEDURE FOR ENRICHMENT OF CIRCULATING TUMOR DNA
US11391742B2 (en) * 2015-02-10 2022-07-19 B.R.A.H.M.S. Gmbh Free histone proteins as biomarkers
EP3294906B1 (en) 2015-05-11 2024-07-10 Natera, Inc. Methods for determining ploidy
WO2016187234A1 (en) 2015-05-18 2016-11-24 Karius, Inc. Compositions and methods for enriching populations of nucleic acids
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers
GB201518674D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
GB201518665D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
CN107858416B (en) * 2016-09-19 2021-05-28 深圳华大生命科学研究院 Biomarker combination for detecting endometriosis and application thereof
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US10894976B2 (en) 2017-02-21 2021-01-19 Natera, Inc. Compositions, methods, and kits for isolating nucleic acids
CN107164508A (en) * 2017-06-16 2017-09-15 上海易毕恩基因科技有限公司 Gene marker for detecting liver cancer and application thereof
CN107385051A (en) * 2017-08-04 2017-11-24 上海易毕恩生物技术有限公司 For detecting liver tumour good pernicious gene marker, kit and detection method
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
EP3759249B1 (en) 2018-03-01 2023-08-30 Epicypher, Inc. Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes
JP2021520816A (en) 2018-04-14 2021-08-26 ナテラ， インコーポレイテッド Methods for Cancer Detection and Monitoring Using Personalized Detection of Circulating Tumor DNA
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
GB201818965D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Method for the detection of colorectal cancer
GB201818963D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Methof for the detection of prostate cancer
GB201906201D0 (en) 2019-05-02 2019-06-19 Belgian Voltion Sprl Method for the detection of protate cancer
GB201906199D0 (en) 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
KR20220111246A (en) 2019-08-27 2022-08-09 벨지언 볼리션 에스알엘 How to Isolate Circulating Nucleosomes
GB201912251D0 (en) 2019-08-27 2019-10-09 Belgian Volition Sprl Method of isolating circulating nucleosomes
TW202134654A (en) 2019-12-02 2021-09-16 比利時商比利時意志有限公司 Use of cell free nucleosomes as biomarkers
EP4239077A3 (en) 2020-03-20 2023-12-06 Belgian Volition SRL Triaging method using cell free nucleosome levels
TW202238131A (en) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 Method for measurment of cell free nucleoprotein chromatin fragments
TW202242130A (en) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 Circulating transcription factor analysis
TW202242145A (en) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 Transcription factor binding site analysis of nucleosome depleted circulating cell free chromatin fragments
TW202242146A (en) 2021-01-13 2022-11-01 比利時商比利時意志有限公司 Method for the detection of lung cancer
GB202108185D0 (en) 2021-06-08 2021-07-21 Belgian Volition Sprl Standardisation of nucleosome assays using biologically derived calibrants
GB202108452D0 (en) 2021-06-14 2021-07-28 Belgian Volition Sprl Triaging method using cell free nucleosome levels
WO2023073179A1 (en) 2021-10-29 2023-05-04 Belgian Volition Srl Homogeneous immunoassay method
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
WO2023170298A1 (en) 2022-03-11 2023-09-14 Belgian Volition Srl Differential diagnosis method
GB202205212D0 (en) 2022-04-08 2022-05-25 Belgian Volition Sprl Method for transplant organ health assessment
WO2024042210A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for measuring cell free chromatin
WO2024133222A1 (en) 2022-12-19 2024-06-27 Belgian Volition Srl Assessment of biological samples for nucleic acid analysis
GB202300607D0 (en) 2023-01-16 2023-03-01 Belgian Volition Srl Proteins and methods for isolating circulating nucleosomes
GB202303562D0 (en) 2023-03-10 2023-04-26 Belgian Volition Sprl Sample collection for liquid biopsy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2652901A1 (en) 1989-10-11 1991-04-12 Pasteur Institut Biological complexes based on nucleosomes, and their applications, especially in the field of in vitro diagnosis of lupus erythematosus disseminatus (LED)
US6630301B1 (en) * 1997-03-14 2003-10-07 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
CA2250118C (en) * 1996-03-26 2009-09-29 Michael S. Kopreski Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
EP1064549B1 (en) * 1998-03-18 2006-06-07 Roche Diagnostics GmbH Detection of apoptotic products
NL1014106C2 (en) 2000-01-18 2001-07-20 Univ Amsterdam Method for detecting a pathological abnormality in a cell, an antibody and an assay kit.
WO2005003381A1 (en) 2003-07-04 2005-01-13 Johnson & Johnson Research Pty. Limited Method for detection of alkylated cytosine in dna
GB0319376D0 (en) * 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
WO2005040814A1 (en) * 2003-10-14 2005-05-06 Cancer Research Technology Limited Methods and means of cancer detection by histone modification
CA2591717A1 (en) * 2004-12-16 2006-07-06 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog lsd1
DE102005034628B4 (en) 2005-07-19 2007-08-23 Epigenomics Ag Method for the investigation of cytosine methylations in DNA
WO2007049286A1 (en) * 2005-10-27 2007-05-03 Tata Memorial Centre A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma
WO2007050706A2 (en) 2005-10-27 2007-05-03 University Of Missouri-Columbia Dna methylation biomarkers in lymphoid and hematopoietic malignancies
JP2009517404A (en) 2005-11-28 2009-04-30 メディミューン，エルエルシー HMGB1 and / or RAGE antagonists and methods of use thereof
DE102006035600B3 (en) 2006-07-27 2007-11-08 Epigenomics Ag Methylation detection, for diagnosis/prognosis of e.g. cancer disease, comprises converting non-methylated cytosine to uracil (nucleic acid) or into other base, so 5-methylcytosine remains unchanged and catalyzing nucleic acid activity
US20080131954A1 (en) * 2006-11-30 2008-06-05 Canon U.S. Life Sciences, Inc. Method of Separating Target DNA from Mixed DNA
CA2683854A1 (en) * 2007-04-11 2008-10-30 Manel Esteller Epigenetic biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer
US7608402B2 (en) * 2008-01-10 2009-10-27 Weiwei Li DNA methylation specific signal amplification
WO2009115313A1 (en) 2008-03-19 2009-09-24 Oryzon Genomics, S.A. Method and composition for methylation analysis
RU2011125306A (en) 2008-11-21 2012-12-27 Юнивёрсити Оф Копенгаген PRIMING AN IMMUNE RESPONSE
AU2010236415A1 (en) 2009-04-14 2011-12-01 The Regents Of The University Of California Histone modification patterns for clinical diagnosis and prognosis of cancer
CN102612652B (en) 2009-08-06 2016-05-04 康奈尔大学 For equipment and the method for analysis of molecules
US20130183662A1 (en) 2010-04-22 2013-07-18 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
WO2011150974A1 (en) 2010-06-03 2011-12-08 Porto Conte Ricerche S.R.L. Biomarkers for lung neuroendocrine tumors
FI20105715A0 (en) 2010-06-18 2010-06-18 Helsingin Yliopisto A polyclonal antibody that binds to acetylated HMGB1
CN101955998A (en) * 2010-07-20 2011-01-26 赵英仁 Method for detecting necrosis degree of hepatic cells through level of plasma free DNA
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
BR112014013082B1 (en) * 2011-12-07 2021-02-02 Singapore Volition Pte Limited use of a nucleosome-protein adduct and methods to detect the presence of a nucleosome-protein adduct
EP3757210B1 (en) 2012-03-02 2022-08-24 Sequenom, Inc. Methods for enriching cancer nucleic acid from a biological sample
GB201303575D0 (en) 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for detecting histone modifications in nucleosomes

Also Published As

Publication number Publication date
SG11201400270PA (en) 2014-03-28
PL2751568T3 (en) 2019-09-30
KR20140078637A (en) 2014-06-25
EP3483608A1 (en) 2019-05-15
BR112014005087A2 (en) 2017-03-28
CN104067124A (en) 2014-09-24
RU2687483C2 (en) 2019-05-14
DK2751568T3 (en) 2019-04-15
CA2845993C (en) 2020-10-13
GB201115095D0 (en) 2011-10-19
RU2017126701A3 (en) 2019-01-31
MX364410B (en) 2019-04-25
JP2014531573A (en) 2014-11-27
EP2751568A1 (en) 2014-07-09
CN104067124B (en) 2018-05-04
TR201904386T4 (en) 2019-05-21
RU2017126701A (en) 2019-01-31
EP3483608B1 (en) 2023-06-07
WO2013030577A1 (en) 2013-03-07
CA2845993A1 (en) 2013-03-07
HRP20190533T1 (en) 2019-06-28
AU2012300641A1 (en) 2014-03-06
ZA201401295B (en) 2014-12-23
KR102074528B1 (en) 2020-02-06
HK1199760A1 (en) 2015-07-17
BR112014005087B1 (en) 2020-12-22
ES2717659T3 (en) 2019-06-24
MX2014002443A (en) 2014-10-13
EP2751568B1 (en) 2018-12-26
RU2014112350A (en) 2015-10-10
US10900064B2 (en) 2021-01-26
AU2012300641B2 (en) 2017-09-28
PT2751568T (en) 2019-04-16
US20140363812A1 (en) 2014-12-11
US20200347435A1 (en) 2020-11-05
JP6322845B2 (en) 2018-05-16
HUE043386T2 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
HK1253354A1 (en) Method for detecting nucleosomes containing histone variants
HK1199760A1 (en) Method for detecting nucleosomes containing nucleotides
HK1199761A1 (en) Method for detecting nucleosomes
HK1249143A1 (en) Method for detecting target nucleic acid
EP2705162A4 (en) Methods for detecting nucleic acid sequence variants
HK1198547A1 (en) Methods for detection of nucleotide modification
HUE047193T2 (en) Method for detecting genetic variation
EP3425063C0 (en) Methods for analyte detection
SG11201400635UA (en) Method for detecting target nucleic acid
EP2674492A4 (en) Method for detecting nucleic acid
SG11201402865XA (en) Method for detecting protein-protein interaction
EP2664917A4 (en) Method for detecting single nucleotide polymorphisms
EP2722674A4 (en) Method for detecting lupus anticoagulants
PL2556168T3 (en) Method for detecting specific nucleic acid sequences
EP2522742A4 (en) Detection method for microarray
IL233868A0 (en) Method for detecting polymavirus reactivation
EP2733483A4 (en) Method for detecting chemical and physical phenomenon, and device therefor
EP2840136A4 (en) Method for detecting dna having microsatellite region
EP2620509A4 (en) Method for detecting mutant dna
GB201119571D0 (en) Detection method